Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation - A novel mechanism for the cardioprotective effects of PPAR agonists

Cardiovascular Research

Volumn 81, Issue 2, 2009, Pages 344-352

  Liu, Hui Rong ^a,c   Tao, Ling ^a   Gao, Erhe ^a   Qu, Yan ^a   Lau, Wayne Bond ^a   Lopez, Bernard L ^a   Christopher, Theodore A ^a   Koch, Walter ^a   Yue, Tian Li ^b   Ma, Xin Liang ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cholesterol homeostasis; Myocardial inflammation; Myocyte apoptosis and necrosis; Reperfusion injury

Indexed keywords

4 AMINOBENZOIC ACID DERIVATIVE; CASPASE 3; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME LOCALIZATION; EXTRACELLULAR SPACE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REPERFUSION INJURY; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CASPASE 3; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYPERCHOLESTEROLEMIA; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, LDL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEROXIDASE; PPAR GAMMA; RABBITS; THIAZOLIDINEDIONES;

EID: 58449125170     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn308     Document Type: Article

References (39)

1. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med 1998;104:2S-5S.
2. Nicholls SJ, Hazen SL. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Jpn J Infect Dis 2004;57:S21-S22.
3. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 2004;24:1309-1314.
4. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004;110:1134-1139.
5. Hazen SL. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 2004;24:1143-1146.
6. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445.
7. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-2142.
8. Stokes KY, Cooper D, Tailor A, Granger DN. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med 2002;33:1026-1036.
9. Williams FM. Neutrophils and myocardial reperfusion injury. Pharmacol Ther 1996;72:1-12.
10. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep 2000;2:327-335.
11. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001;88:10K-15K.
12. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000;101:235-238.
13. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002;90:703-710.
14. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J et al. Pioglitazone, a peroxisome proliferator-activated receptor-fgammag agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;106:3126-3132.
15. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN et al. Antiapoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 2004;62:135-144.
16. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor fgammag ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem 2004;279:8300-8315.
17. Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res 2002;53:414-422.
18. Weyrich AS, Buerke M, Albertine KH, Lefer AM. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. J Leukoc Biol 1995;57:45-55.
19. Ledbetter TK, Paape MJ, Douglass LW. Cytotoxic effects of peroxynitrite, polymorphonuclear neutrophils, free-radical scavengers, inhibitors of myeloperoxidase, and inhibitors of nitric oxide synthase on bovine mammary secretory epithelial cells. Am J Vet Res 2001;62:286-293.
20. Kettle AJ, Gedye CA, Hampton MB, Winterbourn CC. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem J 1995;308(Pt 2):559-563.
21. Myzak MC, Carr AC. Myeloperoxidase-dependent caspase-3 activation and apoptosis in HL-60 cells: protection by the antioxidants ascorbate and (dihydro)lipoic acid. Redox Rep 2002;7:47-53.
22. Wagner BA, Buettner GR, Oberley LW, Darby CJ, Burns CP. Myeloperoxidase is involved in H2O2-induced apoptosis of HL-60 human leukemia cells. J Biol Chem 2000;275:22461-22469.
23. Bekesi G, Heinle H, Kakucs R, Pazmany T, Szombath D, Dinya M et al. Effect of inhibitors of myeloperoxidase on the development of aortic atherosclerosis in an animal model. Exp Gerontol 2005;40:199-208.
24. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-2551.
25. Osborne JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment. J Clin Invest 1989;83:465-473.
26. Jung O, Jung W, Malinski T, Wiemer G, Schoelkens BA, Linz W. Ischemic preconditioning and infarct mass: the effect of hypercholesterolemia and endothelial dysfunction. Clin Exp Hypertens 2000;22:165-179.
27. Sakamoto S, Kashiki M, Imai N, Liang CS, Hood WB Jr. Effects of short-term, diet-induced hypercholesterolemia on systemic hemodynamics, myocardial blood flow, and infarct size in awake dogs with acute myocardial infarction. Circulation 1991;84:378-386.
28. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-625.
29. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991;88:1237-1243.
30. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296:2391-2394.
31. Noctor G, Gomez L, Vanacker H, Foyer CH. Interactions between biosynthesis, compartmentation and transport in the control of glutathione homeostasis and signalling. J Exp Bot 2002;53:1283-1304.
32. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC et al. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ Res 1999;85:950-958.
33. Robinson AJ, Dickenson JM. Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A(1) receptor in DDT(1)MF-2 cells. Eur J Pharmacol 2001;413:151-161.
34. Greenacre SA, Rocha FA, Rawlingson A, Meinerikandathevan S, Poston RN, Ruiz E et al. Protein nitration in cutaneous inflammation in the rat: essential role of inducible nitric oxide synthase and polymorphonuclear leukocytes. Br J Pharmacol 2002;136:985-994.
35. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS et al. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest 2002;109:1311-1319.
36. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998;391:393-397.
37. Kim EJ, Kwon KJ, Park JY, Lee SH, Moon CH, Baik EJ. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res 2002;941:1-10.
38. Kwon G, Xu G, Marshall CA, McDaniel ML. Tumor necrosis factor alpha-induced pancreatic beta-cell insulin resistance is mediated by nitric oxide and prevented by 15-deoxy-Delta12,14-prostaglandin J2 and aminoguanidine. A role for peroxisome proliferator-activated receptor gamma activation and inos expression. J Biol Chem 1999;274:18702-18708.
39. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-fgammag agonist in hypercholesterolemia. Circulation 2003;108:2805-2811.